Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad M. Robins sold 16,680 shares of the firm’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $37.76, for a total transaction of $629,836.80. Following the transaction, the chief executive officer now directly owns 1,798,848 shares in the company, valued at $67,924,500.48. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
ADPT stock opened at $37.32 on Friday. Adaptive Biotechnologies Corporation has a one year low of $15.19 and a one year high of $55.12. The company has a fifty day moving average of $43.50 and a 200-day moving average of $33.83.
Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.25) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.04). Adaptive Biotechnologies had a negative net margin of 87.47% and a negative return on equity of 22.92%. The company had revenue of $20.91 million during the quarter, compared to analyst estimates of $21.52 million. The company’s revenue for the quarter was up 65.1% compared to the same quarter last year. As a group, research analysts expect that Adaptive Biotechnologies Corporation will post -1.05 EPS for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Banque Cantonale Vaudoise acquired a new stake in shares of Adaptive Biotechnologies in the second quarter valued at about $33,000. San Francisco Sentry Investment Group CA lifted its stake in shares of Adaptive Biotechnologies by 148.0% in the second quarter. San Francisco Sentry Investment Group CA now owns 692 shares of the company’s stock valued at $33,000 after purchasing an additional 413 shares during the period. Steward Partners Investment Advisory LLC acquired a new stake in shares of Adaptive Biotechnologies in the first quarter valued at about $27,000. American International Group Inc. raised its position in Adaptive Biotechnologies by 300.0% during the first quarter. American International Group Inc. now owns 1,392 shares of the company’s stock worth $39,000 after acquiring an additional 1,044 shares during the last quarter. Finally, BNP Paribas Arbitrage SA grew its holdings in shares of Adaptive Biotechnologies by 104.6% during the first quarter. BNP Paribas Arbitrage SA now owns 1,614 shares of the company’s stock worth $45,000 after buying an additional 825 shares in the last quarter. Hedge funds and other institutional investors own 76.19% of the company’s stock.
ADPT has been the topic of several research reports. Goldman Sachs Group initiated coverage on shares of Adaptive Biotechnologies in a research report on Wednesday, June 3rd. They set a “buy” rating and a $60.00 price objective on the stock. BTIG Research restated a “buy” rating and issued a $46.00 target price on shares of Adaptive Biotechnologies in a research note on Friday, April 17th. Zacks Investment Research cut shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. ValuEngine cut shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Thursday, July 2nd. Finally, Guggenheim raised their target price on shares of Adaptive Biotechnologies from $44.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, May 19th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $51.25.
Adaptive Biotechnologies Company Profile
Adaptive Biotechnologies Corporation develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions that inform current and future clinical trials, as well as to discover new prognostic and diagnostic signals.
Featured Article: Swap
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.